Prevymis is the brand name for letermovir, an antiviral medicine used to prevent cytomegalovirus (CMV) infection and disease in adult CMV‑seropositive recipients of allogeneic hematopoietic stem cell transplantation, and in certain high‑risk kidney transplant recipients. It inhibits the CMV terminase complex, offering a mechanism distinct from DNA polymerase inhibitors, and is used as prophylaxis in transplant settings where CMV reactivation can lead to serious complications.
Marketed by Merck & Co., Prevymis is available in oral and intravenous formulations for use under specialist supervision. It represents a targeted approach in infectious disease management within the biopharmaceutical sector, intersecting with the broader chemical value chain involved in active pharmaceutical ingredient synthesis and sterile formulation.
